Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapies<\/i><\/p>\n
PLEASANTON, Calif., and SAN RAFAEL, Calif., \u2014 Jan. 8, 2026 \u2014<\/strong> Veeva Systems<\/a> (NYSE: VEEV) and BioMarin Pharmaceutical Inc.<\/a> (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their long-standing relationship.<\/p>\n The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leveraging and providing strategic input into Veeva\u2019s software, data, services, and consulting products.<\/p>\n \u201cThis strategic partnership marks an important next step in our digital evolution,\u201d said Alexander Hardy, President and Chief Executive Officer of BioMarin. \u201cWe are excited by the opportunity to combine our scientific capabilities with Veeva\u2019s technological leadership that we believe will enable us to bring our transformative medicines more quickly to patients around the world.\u201d<\/p>\n \u201cOur partnership with BioMarin has always been guided by a shared set of values, including product excellence, value realization, and customer success,\u201d said Veeva CEO Peter Gassner. \u201cBuilding on this foundation, I look forward to how we can further support BioMarin as they advance important new medicines and reach even more patients around the world.\u201d<\/p>\n About BioMarin<\/strong> About Veeva Systems<\/strong> BioMarin Forward-Looking Statements<\/strong> BioMarin\u00ae, is a registered trademark of BioMarin Pharmaceutical Inc.<\/p>\n Veeva Forward-Looking Statements<\/strong> ###<\/center><\/p>\n
\nBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com<\/a>.<\/p>\n
\nVeeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: BioMarin\u2019s expectations regarding Veeva\u2019s products and services and the expected results or benefits from BioMarin\u2019s use of Veeva\u2019s products and services. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the success of the strategic partnership between BioMarin and Veeva, BioMarin\u2019s ability to utilize Veeva\u2019s products and services to bring BioMarin\u2019s medicines more quickly to patients, and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin’s Quarterly Report on Form 10-Q for the quarter ended October 31, 2025, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n